Eli Lilly Cost of sales, operating expenses, and other-net increased by 6.3% to $11.03B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 29.8%, from $8.49B to $11.03B. Over 4 years (FY 2021 to FY 2025), Cost of sales, operating expenses, and other-net shows an upward trend with a 15.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A lower total relative to revenue indicates higher overall operational efficiency and better profit margins.
This is an aggregated view of all operating costs, including cost of goods sold, R&D, SG&A, and other net operating char...
Company-specific aggregation; comparable to 'Total Operating Expenses' at other firms.
is_lly_cost_of_sales_operating_expenses_and_other_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.15B | $5.53B | $6.16B | $5.76B | $5.40B | $5.38B | $5.21B | $5.43B | $6.22B | $9.07B | $6.84B | $6.23B | $7.79B | $9.85B | $8.49B | $9.27B | $8.78B | $10.37B | $11.03B |
| QoQ Change | — | +7.4% | +11.4% | -6.6% | -6.2% | -0.4% | -3.2% | +4.3% | +14.6% | +45.8% | -24.5% | -9.0% | +24.9% | +26.5% | -13.8% | +9.2% | -5.3% | +18.1% | +6.3% |
| YoY Change | — | — | — | — | +4.9% | -2.7% | -15.5% | -5.7% | +15.3% | +68.7% | +31.5% | +14.8% | +25.1% | +8.6% | +24.1% | +48.8% | +12.8% | +5.3% | +29.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.